Hjem › Pankreaskreft › Kentucky
Kliniske studier for Pankreaskreft i Kentucky
13 studier for Pankreaskreft søker deltakere på steder i Kentucky.
Byer i Kentucky
Offisiell studietekst (engelsk)
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- University of Kentucky/Markey Cancer Center, Lexington
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05372614A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- University of Kentucky Research Foundation, Lexington
- University of Kentucky Healthcare - Markey Cancer Center, Lexington
- University of Kentucky Medical Center, Lexington
- og 1 flere
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06989437A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
- Saint Elizabeth Medical Center, Inc. DBA St. Elizabeth Health Care, Edgewood
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07409272Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
- University of Kentucky/Markey Cancer Center, Lexington
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. aug. 2026 · NCT06958328EXoPERT EMERALD Clinical Study
- Lexington VA Healthcare System, Lexington
- KCTL, Louisville
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 45 og eldre · Alle kjønn · Oppdatert 1. jul. 2026 · NCT07186296Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Norton Cancer Institute /ID# 248903, Louisville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 23. jun. 2026 · NCT05005403Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
- Flaget Memorial Hospital, Bardstown
- Commonwealth Cancer Center-Corbin, Corbin
- Saint Joseph Hospital, Lexington
- og 4 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. mai 2026 · NCT06998940Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
- University of Kentucky/Markey Cancer Center, Lexington
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 31. mar. 2026 · NCT06807437A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
- Ohio State University-Telemedicine, Lexington
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. feb. 2026 · NCT06906562cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist Corbin, Corbin
- Baptist Hardin, Elizabethtown
- Baptist Lexington, Lexington
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 og eldre · Alle kjønn · Oppdatert 20. jan. 2026 · NCT05366881GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
- University of Kentucky, Lexington
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 16. des. 2025 · NCT05391126Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
- University of Louisville, Louisville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 29. okt. 2025 · NCT03484299American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry
- University of Louisville, Louisville
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 25. feb. 2025 · NCT02674100Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.